Clinical Scorecard: Assessment of Potential Vaccine Targets and Genomic Characteristics of Pediatric Invasive Streptococcus Agalactiae in Japan
At a Glance
Category
Detail
Condition
Pediatric invasive infections caused by Streptococcus agalactiae (Group B Streptococcus, GBS), including sepsis and meningitis
Key Mechanisms
Vertical maternal transmission and potential alternative transmission routes; antimicrobial resistance including multidrug-resistant clones; genomic diversity and persistence of specific lineages
Target Population
Children aged ≤15 years with invasive GBS infections in Japan
Care Setting
Hospital-based diagnosis and management including tertiary children's and university hospitals
Key Highlights
Estimated vaccine coverage was 98.3% for the hexavalent polysaccharide vaccine and 94.9% for the GBS-NN/NN2 protein vaccine in pediatric invasive GBS isolates.
High rates of erythromycin (61.2%) and clindamycin (43.5%) resistance observed, with predominance of a multidrug-resistant CC17 clone harboring ermB and tetO genes.
Genomic analysis revealed evidence of nosocomial transmission and persistent regional circulation of ST17 and ST23 lineages, highlighting complex transmission dynamics beyond maternal colonization.
Guideline-Based Recommendations
Diagnosis
Perform serotyping, antimicrobial susceptibility testing, and whole-genome sequencing of GBS isolates from sterile specimens in pediatric patients.
Classify GBS infections by age onset: early-onset disease (≤6 days), late-onset disease (7–89 days), and very late-onset disease (≥90 days).
Management
Use intrapartum antibiotic prophylaxis (IAP) to prevent early-onset disease, employing risk-based or screening-based approaches.
Consider high rates of clindamycin resistance when selecting second-line antibiotics for IAP or treatment.
Support maternal immunization with candidate GBS vaccines (polysaccharide hexavalent or protein-based GBS-NN/NN2) to provide passive immunity to infants.
Monitoring & Follow-up
Conduct ongoing genomic surveillance to monitor antimicrobial resistance patterns and circulating GBS lineages.
Investigate potential nosocomial and environmental transmission routes to inform infection control strategies.
Risks
Potential for serotype replacement or capsular switching reducing vaccine effectiveness.
Unidentified transmission routes beyond maternal colonization, including caregiver contact and environmental exposure.
Emergence and spread of multidrug-resistant GBS clones complicating treatment.
Patient & Prescribing Data
Children aged ≤15 years with invasive GBS infections in Japan
High resistance rates to erythromycin and clindamycin necessitate careful antibiotic selection; maternal vaccination with hexavalent polysaccharide or GBS-NN/NN2 protein vaccines shows promise for broad coverage and passive infant protection.
Clinical Best Practices
Implement maternal GBS vaccination programs targeting prevalent serotypes and conserved protein antigens to reduce neonatal and infant invasive disease.
Maintain and expand genomic surveillance to detect emerging resistant clones and transmission patterns.
Use antibiotic susceptibility data to guide intrapartum prophylaxis and treatment decisions, considering local resistance profiles.
Investigate and address non-maternal transmission routes, including nosocomial and environmental reservoirs, to enhance prevention.
